Remission of refractory minimal change nephrotic syndrome after basiliximab therapy

Pediatric Nephrology

Volumn 24, Issue 7, 2009, Pages 1403-1407

  Park, Sung Shin ^a   Hahn, Won Ho ^a   Kim, Sung Do ^a   Cho, Byoung Soo ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Anti interleukin 2 receptor antibody; Basiliximab; Cyclosporine resistant nephrotic syndrome; Minimal change nephrotic syndrome; Steroid resistant nephrotic syndrome

Indexed keywords

ALBUMIN; BASILIXIMAB; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE;

ALBUMIN BLOOD LEVEL; ANAMNESIS; ARTICLE; BACTERIAL INFECTION; CASE REPORT; CATARACT; CHILD; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; EDEMA; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; LONG TERM CARE; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; REMISSION; SCROTAL SWELLING; SINGLE DRUG DOSE; URINARY EXCRETION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; NEPHROSIS, LIPOID; RECOMBINANT FUSION PROTEINS; RIBONUCLEOSIDES;

EID: 67349105081     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-009-1145-6     Document Type: Article

References (23)

1. Vogt BA, Avner ED (2007) Nelson textbook of pediatrics, 18th edn. Saunders, Philadelphia, pp 2190-2195
2. Shalhoub RJ (1974) The pathogenesis of lipoid nephrosis. Lancet 2:556-560
3. Sahali D, Pawlak A, Valanciuté A, Grimbert P, Lang P, Remy P, Bensman A, Guellaën G (2002) A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol 13:1238-1247
4. Cunard R, Kelly CJ (2002) T cells and minimal change disease. J Am Soc Nephrol 13:1409-1411
5. Grimbert P, Audard V, Remy P, Lang P, Sahali D (2003) Recent approaches to the pathogenesis of minimal change nephrotic syndrome. Nephrol Dial Transplant 18:245-248
6. Walker KB, Potter JM, House AK (1987) Interleukin 2 synthesis in the presence of steroids: A model of steroid resistance. Clin Exp Immunol 68:162-167
7. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY (1993) Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 151:3460-3466
8. Zachwieja J, Bobkowski W, Dobrowolska-Zachwieja A, Lewandowska-Stachowiak M, Zaniew M, Maciejewski J (2002) Intracellular cytokines of peripheral blood lymphocytes in nephrotic syndrome. Pediatr Nephrol 17:733-740
9. Shimoyama H, Nakajima M, Naka H, Maruhashi Y, Akazawa H, Ueda T, Nishiguchi M, Yamoto Y, Kamitsuji H, Yoshioka A (2004) Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome. Pediatr Nephrol 19:1115-1121
10. Aviles DH, Vehaskari M, Manning J, Ochoa AC, Zea AH (2004) Decreased expression of T-cell NF-kappa B p65 subunit in steroid-resistant nephrotic syndrome. Kidney Int 66:60-67
11. Araya CE, Wasserfall CH, Brusko TM, Mu W, Segal MS, Johnson RJ, Garin EH (2006) A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 21:603-610
12. Chapman TM, Keating GM (2003) Basiliximab: A review of its use as induction therapy in renal transplantation. Drugs 63:2803-2835
13. Boggi U, Danesi R, Vistoli F, Del Chiaro M, Signori S, Marchetti P, Del Tacca M, Mosca F (2004) A benefit-risk assessment of basiliximab in renal transplantation. Drug Saf 27:91-106
14. Swiatecka-Urban A (2003) Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: Current status. Paediatr Drugs 5:699-716
15. Sahali D, Pawlak A, Le Gouvello S, Lang P, Valanciuté A, Remy P, Loirat C, Niaudet P, Bensman A, Guellaen G (2001) Transcriptional and post-transcriptional alterations of Ikappa B alpha in active minimal-change nephrotic syndrome. J Am Soc Nephrol 12:1648-1658
16. Briggs WA, Han SH, Miyakawa H, Burdick JF, Kwon HM (1999) Effects of glucocorticoids and cyclosporine on IL-2 and I kappa B alpha mRNA expression in human peripheral blood mononuclear cells. J Clin Pharmacol 39:119-124
17. Kalli K, Huntoon C, Bell M, McKean DJ (1998) Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 receptor-initiated regulation of IL-2 gene expression by NK-kappa B. Mol Cell Biol 18:3140-3148
18. Marienfeld R, Neumann M, Chuvpilo S, Escher C, Kneitz B, Avots A, Schimpl A, Serfling E (1997) Cyclosporin A interferes with the inducible degradation of NF-kappa B inhibitors, but not with the processing of p105/NF-kappa B1 in T cells. Eur J Immunol 27:1601-1609
19. McKay LI, Cidlowski JA (1998) Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: Mechanism of mutual antagonism. Mol Endocrinol 12:45-56
20. Nagai T, Goto Y, Haba T, Uchida K (2005) The effect of urinary protein excretion in post-renal transplant recurrent nephrotic syndrome on basiliximab pharmacokinetics and pharmacodynamics in a pediatric patient. Transplant Proc 37:879-880
21. Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, Martin PY (2007) Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 20:102-105
22. Yabu JM, Ho B, Scandling JD, Vincenti F (2008) Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8:222-227
23. François H, Daugas E, Bensman A, Ronco P (2007) Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: First case report and pathophysiological considerations. Am J Kidney Dis 49:158-161